Similarly, pooled data showed a nonsignificant difference in relative risk for hypercalcemia between patients taking PTH therapy and controls (RR = 3.98; 95% CI, 0.77 to 20.55; p = 0.099; I2 = 56.5%; p = 0.130). The gene discussed is PTH; the disease is hypercalcemia disease.